At a press conference on Cuban television, Dr. Rolando Ochoa, a researcher with the Finlay Vaccines Institute (IFV) and project leader, explained that Soberana Plus has been designed for convalescents and as reinforcement for those who have been vaccinated with Soberana 02 in its phase III of clinical trials.

Soberana Plus was recently approved for phase II of clinical trials, and will be administered to 450 volunteers who suffered from Covid-19 with a mild, moderate or asymptomatic clinical history.

‘It will be a multicenter, adaptive study in parallel random groups, a double-blind and control study with a placebo,’ Ochoa noted.

The study involves patients aged 19-80 who were discharged from hospitals at least two months before receiving a single dose of Soberana Plus.

jg/jcm/cdg